EU invests €8.5 million in the fight against poverty related diseases

EU invests €8.5 million in the fight against poverty related diseases

Berlin, 18 November 2013

In November 2013 the collaborative infrastructure programme ‘European Research Infrastructures for Poverty Related Diseases’ (EURIPRED) will start in order to reinforce the knowledge infrastructure across diseases. The ultimate aim is to speed the development of new tools (vaccines, drugs, microbicides) to combat Tuberculosis, HIV, Malaria, Hepatitis B and Hepatitis C. EURIPRED is co-funded with €8.5M by the European Commission. Scientists from 17 research partners in 10 countries will collaborate in this new programme.

HIV/AIDS, Tuberculosis (TB) and Malaria alone account for 3.4 million deaths worldwide every year. Despite substantial efforts made in recent years, these poverty related diseases are still spreading. Among the reasons are the absence of preventing vaccines for all diseases, the sometimes tough and burdensome treatment courses and the underdiagnoses. Therefore new tools are urgently required to combat these diseases.

Several organisations in Europe and beyond, are working on the development of these new tools. For HIV, TB and Malaria there are well developed infrastructures for the development of the specific tools each, where research organisations share knowledge to accelerate development. However, it is no common use that they benefit from other diseases’ experiences, because there is no single infrastructure to coordinate the development of all these new tools from discovery to clinical trials. EURIPRED aims to fill this gap, by integrating international resources in this field, including for the development of Hepatitis B and Hepatitis C which both could very well benefit from the experiences in other diseases.

"By creating partnerships between European scientists and international research teams from disease endemic countries, we expect to speed up the development of new vaccines, drugs and microbicides," says Dr Meghna Ramaswamy, Coordinator of EURIPRED and Scientific Lead at the Centre for AIDS Reagents, at the National Institute of Biological Standards and Control (NIBSC) in London. "Besides that, by minimising fragmentation and duplication of research efforts and pooling fragmented resources EURIPRED can improve research efficiency and effectiveness."

EURIPRED comprises a team of leading European scientists, institutes and networks in the field of poverty related diseases. The project is reinforced by key partners in the endemic countries China, Russia and Kenya. Besides knowledge exchange, concrete objectives are exchange, selection, development, production and validation of reference reagents, assays and standards and training.

Within the EURIPRED project JPT Peptide Technologies, a recognized technology leader for peptide based immune monitoring and biomarker discovery reagents and approaches, will design and contribute easy to use peptide kits and tools for profiling humoral and cellular immune responses as well as conduct training courses to use these kits in biological assays. Holger Wenschuh, CEO at JPT says: "We are honored to be part of this consortium helping to accelerate the fight against some of the most critical poverty related diseases. We truly believe that our technologies and previous experience to support similar operations such as the NIH AIDS Reagent Program will be beneficial for the development of this exciting endeavour."

About JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG (Mainz, Germany), is a DIN ISO 9001:2008 certified research and development partner and innovative service provider for peptide related projects.  JPT’s key technologies SPOT™ – for ultra-high-throughput peptide synthesis and screening, PepStar™– for high-content peptide microarrays, PepTrack™  - for flexible peptide library assembly, PepMix™– for antigen specific T-cell stimulation using peptide pools, and SpikeTide™– for protein biomarker quantification accelerate research and development in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimization, enzyme profiling and proteomics.

For further information please contact:
Dr. Holger Wenschuh, CEO
12555 Berlin

Tel: +49 30 6392 5500
Fax: +49 30 6392 5501


Stay in touch and be the first to receive the latest news!